Preliminary immunohistochemical characterization of a monoclonal antibody (PRO:4-216) prepared from human prostate cancer nuclear matrix proteins.

[1]  E. Messing,et al.  Use of a new tumor marker, urinary NMP22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment. , 1996, The Journal of urology.

[2]  M. Becich,et al.  Bladder cancer-associated nuclear matrix proteins. , 1996, Cancer research.

[3]  K. Pienta,et al.  Unique Nuclear Matrix Protein Alterations in Head and Neck Squamous Cell Carcinomas: Intermediate Biomarker Candidates , 1996, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[4]  W. Dinjens,et al.  EXPRESSION OF NUCLEOPHOSMIN/B23 IN NORMAL AND NEOPLASTIC COLORECTAL MUCOSA , 1996, The Journal of pathology.

[5]  J. Rüschoff,et al.  In vitro and ex vivo expression of nucleolar proteins B23 and p120 in benign and malignant epithelial lesions of the prostate. , 1995, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[6]  J. Epstein,et al.  The Utility of Basal Cell—Specific Anti‐Cytokeratin Antibody (34βE12) in the Diagnosis of Prostate Cancer: A Review of 228 Cases , 1995, The American journal of surgical pathology.

[7]  J. Oesterling,et al.  The clinical usefulness of prostate specific antigen: update 1994. , 1994, The Journal of urology.

[8]  M. Meneghini,et al.  Nuclear matrix proteins in human colon cancer. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[9]  A W Partin,et al.  Serum PSA after anatomic radical prostatectomy. The Johns Hopkins experience after 10 years. , 1993, The Urologic clinics of North America.

[10]  K. Pienta,et al.  Nuclear matrix proteins in normal and breast cancer cells. , 1993, Cancer research.

[11]  A W Partin,et al.  Nuclear matrix protein patterns in human benign prostatic hyperplasia and prostate cancer. , 1993, Cancer research.

[12]  A. Partin,et al.  Use of nuclear morphometry, gleason histologic scoring, clinical stage, and age to predict disease‐free survival among patients with prostate cancer , 1992, Cancer.

[13]  E. Tan,et al.  Nucleolar antigens and autoantibodies in hepatocellular carcinoma and other malignancies. , 1992, The American journal of pathology.

[14]  W. Catalona,et al.  Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. , 1991, The New England journal of medicine.

[15]  A W Partin,et al.  A comparison of nuclear morphometry and Gleason grade as a predictor of prognosis in stage A2 prostate cancer: a critical analysis. , 1989, The Journal of urology.

[16]  K. Pienta,et al.  Cancer as a disease of DNA organization and dynamic cell structure. , 1989, Cancer research.

[17]  M. Resnick,et al.  A Multidisciplinary Analysis of Controversies in the Management of Prostate Cancer , 1988, Springer US.

[18]  J. Epstein,et al.  Nuclear roundness factor. A predictor of progression in untreated stage A2 prostate cancer , 1984, Cancer.

[19]  T. Boulikas,et al.  Silver staining of proteins in polyacrylamide gels. , 1981, Analytical biochemistry.

[20]  H. Busch,et al.  Nucleolar localization of protein B23 (37/5.1) by immunocytochemical techniques. , 1981, Life sciences.

[21]  C. Milstein,et al.  Antibodies to major histocompatibility antigens produced by hybrid cell lines , 1977, Nature.

[22]  A. I. Spriggs.  The Cell in Health and Disease , 1970 .

[23]  J. Epstein,et al.  Immunoreactivity for prostate‐specific antigen and prostatic acid phosphatase in adenocarcinoma of the prostate: Relation to progression following radical prostatectomy , 1998, The Prostate.

[24]  J. Briggman,et al.  Utilization of nuclear matrix proteins for cancer diagnosis. , 1996, Critical reviews in eukaryotic gene expression.

[25]  G. Stein,et al.  Nuclear matrix proteins distinguish normal diploid osteoblasts from osteosarcoma cells. , 1994, Cancer research.

[26]  T. Tong,et al.  Cancer statistics, 1994 , 1994, CA: a cancer journal for clinicians.

[27]  J. Rüschoff,et al.  [In vivo and ex vivo expression of nucleolar proliferation-associated antigens (p120, B23) in the prostate]. , 1993, Verhandlungen der Deutschen Gesellschaft fur Pathologie.

[28]  S. Penman,et al.  Nuclear matrix proteins reflect cell type of origin in cultured human cells. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[29]  D. S. Coffey,et al.  Prostate Cancer: The Magnitude of the Problem in the United States , 1988 .